Innovative Medical Focus Presidio Medical specializes in developing cutting-edge neuromodulation platforms targeting diseases of undesired neural activity, with an initial focus on chronic pain, positioning it as a leader in transformative neurological treatments.

Strong Funding Trajectory The company has secured significant investment rounds, totaling $102 million, indicating robust financial backing and validation from investors, which supports ongoing product development and potential scaling efforts.

Leadership Expansion Recent high-profile appointments to the board of directors, including experienced industry leaders like Richard J. Buchholz and David Neustaedter, suggest strategic growth initiatives and increased credibility in the medical device sector.

Growth and Development As a clinical-stage private company with an employee base of up to 200, Presidio Medical is positioned for rapid innovation and potential commercialization in neuromodulation therapies, creating opportunities for partnerships and clinical collaborations.

Market Opportunity With a revenue range of $10M to $25M and focus on neuromodulation solutions, there are substantial opportunities to engage with the healthcare providers and device distributors involved in pain management and neurological disorder treatments.